



Telephone: (800) 514-0083 option 2  
 Fax: (866) 374-1579

**Palivizumab (Synagis)**  
**Prior Authorization Form/ Prescription**

Date: \_\_\_\_\_ Date Medication Required: \_\_\_\_\_  
 Ship to:  Physician  Patient's Home  Other \_\_\_\_\_

**Patient Information**

Last Name:	First Name:	Middle:	DOB: ____/____/____
Address:		City:	State: _____ Zip: _____
Daytime Phone:	Evening Phone:		Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female

**Insurance Information (Attach Copies of cards)**

Primary Insurance:		Secondary Insurance:	
ID #	Group #	ID #	Group #
City:	State:	City:	State:

**Physician Information**

Name:	Specialty:	NPI:
Address:		City: _____ State: _____ Zip: _____
Phone # ( _____ )	Secure Fax #: ( _____ )	Office contact: _____

**Primary Diagnosis**

ICD-10 Code: \_\_\_\_\_

Congenital Heart Disease   
  Chronic Lung Disease arising in the perinatal period   
  Congenital Abnormality of Respiratory System   
  Cystic Fibrosis  
 Neuromuscular disorder   
  Profoundly immunocompromised  
 < 24 weeks of gestation   
  24 weeks gestation   
  25-26 weeks of gestation   
  27-28 weeks of gestation  
 29-30 weeks of gestation   
  31-32 weeks of gestation   
  33-34 weeks of gestation   
  35-36 weeks of gestation  
 37+ weeks of gestation   
  Other \_\_\_\_\_

**Clinical Information**

\*\*\*\*\* Please submit supporting clinical documentation \*\*\*\*\*

Patient's gestational age (Required): \_\_\_\_\_ weeks \_\_\_\_\_ days Birth Weight: \_\_\_\_\_ g/kg/lbs Current Weight: \_\_\_\_\_ g/kg/lbs Date Recorded: \_\_\_\_\_

Did the patient spend time in the NICU?  Yes  No **If yes, provide NICU name and attach discharge summary:** \_\_\_\_\_

Was this season's first Synagis dose given in the NICU?  Yes  No **If yes, provide date(s):** \_\_\_\_\_ Expected date of first/next injection: \_\_\_\_\_

**Patient Evaluation (Check all that apply and submit clinical documentation):**

- Hospitalization for RSV infection this season?
  - Diagnosis of hemodynamically significant Congenital Heart Disease (CHD) and < 12 months of age at start of RSV Season and patient has the following conditions (Check all that apply):
    - Moderate-Severe Pulmonary Hypertension
    - Cyanotic Heart Disease (if consulted with a pediatric cardiologist)
    - Acyanotic heart disease medications to control CHF (list medications): \_\_\_\_\_ Last Date Received: \_\_\_\_\_ **AND** require cardiac surgical procedures
    - Age < 24 months; undergoing cardiac transplantation or cardio-pulmonary bypass during the current RSV season
  - Diagnosis of Chronic Lung Disease\* and less than 12 months at start of RSV Season  
 \*CLD is generally defined as: Infants <32 weeks, 0 days with oxygen requirement > 21% for at least the first 28 days of birth. CLD is NOT defined as asthma, croup, recurrent upper respiratory infections, chronic bronchitis, bronchiolitis, or a history of a previous RSV infection
  - Diagnosis of Chronic Lung Disease\* and between 12 to less than 24 months at start of RSV Season and receiving treatment of (check all that apply and provide last date received):
    - Supplemental oxygen, Date: \_\_\_\_\_
    - Chronic corticosteroid therapy, Date: \_\_\_\_\_
    - Diuretic therapy, Date: \_\_\_\_\_
  - Diagnosis of Cystic Fibrosis and less than 12 months of age at start of RSV season?
    - Clinical evidence of CLD
    - Nutritional compromise: Explain: \_\_\_\_\_
  - Diagnosis of Cystic Fibrosis and between 12 to less than 24 months of age at start of RSV season
    - Manifestations of severe lung disease (hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest radiography or CT that persists when stable)
    - Weight for length less than 10<sup>th</sup> percentile
  - Diagnosis of condition that impairs the ability to clear secretions from the upper airway because of ineffective cough **AND** less than 12 months at the start of RSV season
    - Congenital anomaly that impairs the ability to clear secretions from the upper airway because of ineffective cough
    - Neuromuscular condition
  - Patient be profoundly immunocompromised during the RSV season (e.g., due to solid organ or hematopoietic stem cell transplantation, chemotherapy, severe combined immunodeficiency, chronic granulomatous disease). **If yes, provide chart notes documenting care plan**
  - Patient is an Alaska native or American Indian.
- Please list other medical history and/or risk factors: \_\_\_\_\_

**Home Health Coordination**

Please note, separate authorization is required for injection training/home health visit. Call (866) 296-8731 for prior authorization

Specialty Pharmacy to coordinate injection to coordinate injection training/home health nurse visit as necessary. Please list Agency of choice: \_\_\_\_\_

**Prescription Information**

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
Synagis	<input type="checkbox"/> 50mg <input type="checkbox"/> 100mg	Inject 15 mg/kg IM one time per month		

Prescriber has counseled parent/guardian on Synagis therapy and the specialty pharmacy may contact parent/guardian



Telephone: (800) 514-0083 option 2  
Fax: (866) 374-1579

**Palivizumab (Synagis)**  
**Prior Authorization Form/ Prescription**

Date: \_\_\_\_\_ Date Medication Required: \_\_\_\_\_  
Ship to:  Physician  Patient's Home  Other \_\_\_\_\_

Physician's Signature \_\_\_\_\_ Date: \_\_\_\_\_  DAW